Articles related to Endocrinology, Diabetes, Metabolism

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

A primary care physician describes combining nutrition counseling, individualized monitoring, and pharmacotherapy in obesity care. The interview offers a practice philosophy rather than comparative evidence supporting one treatment strategy.

Experts highlighted ongoing barriers and knowledge gaps affecting reproductive care for transgender and gender-diverse patients while outlining strategies to support pregnancy, postpartum care, and fertility discussions in affirming clinical environments.

A systematic review and meta-analysis found that inclisiran significantly reduced LDL cholesterol compared with placebo across diverse hyperlipidemia populations. Long-term cardiovascular outcome data remain limited despite consistent lipid-lowering efficacy and favorable safety findings.

Discontinuing statins in adults 75 years and older without prior cardiovascular disease did not increase mortality or major cardiovascular events over three years in a randomized trial. LDL cholesterol rose substantially after discontinuation, and longer-term effects remain uncertain.

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.